Foresight Diagnostics’ Post

PinPoint is now live on Crowdcube - and we’ve already surpassed our initial raise target within a day of launching to the public. Thank you to everyone who has already invested - we look forward to welcoming you as shareholders. We’re continuing to welcome investment beyond our initial target, as every new shareholder will be contributing to our impact on patients and healthcare services. We’re crowdfunding to grow PinPoint in multiple ways, which we share more about on our Crowdcube pitch page. Just click below to access our pitch, and join us from just £12.36 https://lnkd.in/ePySz2pK #crowdfunding #EIS #investment #raising #NHS #cancer #AI #machinelearning #medtech Don’t invest unless you’re prepared to lose all the money you invest

The countdown is on! We're less than one month away from the highly anticipated Leveraged Finance Fights Melanoma (LFFM) event, set to take place on June 12, 2024, at the iconic The Museum of Modern Art. For over a decade, leaders from the leveraged finance, private equity, and investment communities have come together to raise crucial funds for melanoma research. LFFM's support has fueled groundbreaking advancements in melanoma diagnosis, detection, prevention, and treatment. What's even more remarkable is the ripple effect of these investments, with treatments initially tested in melanoma now informing treatment protocols for 30 other cancers and diseases. We extend our deepest gratitude to the exceptional leadership of our LFFM event co-chairs: Clare B. (MidCap Financial) Brendan Dillon (Veritas Capital) Kerry Dolan (Brinley Partners) Lee Grinberg (Elliott Investment Management L.P.) Jason Kanner (Kirkland & Ellis) Matthew Manin (Apollo Global Management, Inc.) Eliza McDougall (White & Case LLP & Case) Erwin Mock (Thoma Bravo) George Mueller (KKR) Geoff Oltmans (Silver Lake) Kevin Pluff (HPS Investment Partners, LLC) Jeff Rowbottom (General Atlantic Credit) Ian Schuman (Latham & Watkins) Brian Steinhardt (Simpson Thacher & Bartlett LLP) Cade Thompson (KKR) Trevor Watt (Hellman & Friedman) Eric Wedel (Paul, Weiss, Rifkind, Wharton & Garrison LLP) Want to be a part of this purpose-driven networking experience? Reach out to Janine Rauscher ([email protected]) to learn more about sponsorship opportunities and secure your spot. #LFFM #MelanomaResearch #CureMelanoma #LeveragedFinance #PrivateEquity #Finance #Fundraising

Xgenera (Future Worlds Cohort 23) are fundraising for their seed round. If you're an early stage #medtech or #biotech #investor, get in touch with Xgenera to hear more about their revolutionary blood-based, multi-cancer early diagnostic (MCED) test. You can read more here: https://lnkd.in/eZZz_3US If you know investors who may be interested, please share this post. #cancer #fundraising #startup #investment #Southampton #startup #FounderFirst

What Xgenera are doing with their multi-cancer early diagnostic test is amazing and has the potential to positively impact the lives of so many people. If you know anyone who would be interested in investing, make sure they check Xgenera out. Also, another great startup emerging from University of Southampton. #startup #investment #Southampton #cancerprevention

We are deeply encouraged that REPAIR Impact Fund portfolio company Revagenix, Inc. has raised a Series B, which along with substantial non-dilutive financing will take multiple programs to clinical proof of concept. Novo Holdings was the sole investor in the Series A in 2020, and since then the management team has advanced several antibiotic discovery programs into late pre-clinical testing, and attracted Tenmile Capital to lead the Series B. Revagenix, like the bird Phoenix, rose from the ashes of the bankruptcy of Archaogen, which had successfully developed and launched the antibiotic Plazomicin. The team led by Ryan Cirz knows both what it takes to create a novel antibiotic but just as importantly also what doesn’t fly commercially and financially.  New members of the board of directors include Mike Lamprecht from Tenmile, Bruce Montgomery, an advisor to Novo Holdings, and Cristina Larkin, previously COO of Spero Therapeutics. Raising money for antibiotic companies is unbelievably difficult right now. The Revagenix management team has shown that with the right team and science it is still hard but possible. Further perspectives here: https://lnkd.in/d5HD7Egp

We're delighted that the ProVascTec campaign has now reached its target and is #overfunding. It's open until midnight on Wednesday if anyone is still interested in investing in this very exciting #Cork-based medtech company. - An outstanding, multi-PhD Founding Team - A cell therapy spin-out from UCC - Patent-protected technology (already granted in Europe and the USA) - Global market size of €14 billion - An Enterprise Ireland High Potential Start-Up company - Already received €100,000 from NLC Health Ventures (a Dutch-based venture capital firm) - Qualifies for a 50% EIIS Tax Refund for private investors - A pre-money Valuation of €5.3m - NLC Health Ventures investing again in this round on the exact same terms as private investors - Potential for 30x return on your investment Visit here to invest: https://lnkd.in/gaAwPpiH

An Excerpt From the Crowdfunding Real Estate Guide to Success Fear Defined - Dictionary.com says fear is a distressing emotion aroused by impending danger, evil, pain, etc., whether the threat is real or imagined; the feeling or condition of being afraid. You, I, we, they, get afraid of something, whether the threat is real or imagined. I guess my view of fear has changed to being unaffected because cancer is my daily battle. As more test come and go its now a battle of my mind to not allow it to drift outside of healing, no matter how long it takes. https://lnkd.in/gUsqt7ts #eyecatcher #cancer #warrior #monetize #expenses #crowdfunding #guide #support #funding #investing #portfolios #realestate #bonds #business #success #investments #bible 

Here is an idea for International Women's Day. Make an investment that could make a difference in the future to someone you know, or someone in your family. Ablatus - creators of Luna are crowdfunding their latest raise on Crowdcube. They are developing a device for the much-improved treatment of Uterine Fibroids, and I'm invested. I know I could lose my investment, but it could also be a very successful one. As their CEO Chung Looi put it the other day in a great article "Women's Health is a necessity, not a charity". So, if you want to make a difference, take a look at this opportunity; it is close to its target now, so push it over the line today, and don't miss out! #womenshealth #internationalwomensday #investmentopportunities

Check out this week's Healthcare Report where we discuss news surrounding Eli Lilly and Company! Eli Lilly's Alzheimer's drug, donanemab, may outperform Leqembi in effectiveness and frequency of use. Charities have created SCI Ventures, an investment fund for spinal cord injury treatments. Also, comment your email address to be a part of our mailing list! Analyst: Pakhi Sahni

🦾 Our Army Of 5,000 Shareholders Is Growing By The Day... Discover how our army of loyal Cytonics Corporation shareholders is propelling us towards revolutionizing regenerative medicine! 🖇 invest.cytonics.com 💸 Fundraising Triumphs: A Collective Achievement To date, we have raised over $25M in pursuit of developing the first and only therapy for osteoarthritis. This monumental effort boasts: ➡️ A $4M investment from Synthes (a medical device company acquired by Johnson and Johnson for $19B), alongside ➡️ $10M raised through equity crowdfunding, with ➡️ Over 100 orthopedic surgeons who utilize our APIC therapy for osteoarthritis and understand the significance of our drug development program. Our Cytonics family has expanded to over 5,000 shareholders who have played a pivotal role in our success through repeat investment, an outpouring of encouragement, and spreading the word. Every investor, regardless of the size of their committment, is a part of our family and treated as such. The current round has welcomed over 1,100 new shareholders, many of whom are placing their first equity crowdfunding investment (292 to be exact)! 🔍 A Closer Look Into Our Campaign The unwavering loyalty and commitment of our shareholders is a testament to the deep trust and shared goals that bind us. This round alone has raised over $2.7M from more than 1,100 investors, 60% of whom are returning shareholders. This remarkable rate of recurring investment is not just a metric of success but a beacon of the belief in our mission, confidence in management, and the impact of our research. ❤️ In Gratitude Your continued support and belief in Cytonics are more than just a financial decision; you are the driving force behind our relentless pursuit of improving human well-being. It's a shared journey towards creating long-term value and making a significant impact on the lives of those affected by osteoarthritis. #biotechnology #arthritis #investing #crowdfunding #venturecapital #healthcare #drugdevelopment #clinicaltrials #regenerativemedicine